The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2020 | Defining newly diagnosed high-risk MM
Joshua Richter, MD, Mount Sinai Medical Center, New York, NY, gives an overview of his presentation at ASCO 2020 around defining newly diagnosed high-risk multiple myeloma, and the importance of unifying these definitions to make comparisons between clinical trials and real-world data moving forward. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
